Below is a selection of available results:

Roger Tell, et al. “Folate pathway gene expression in metastatic colorectal cancer patients treated with arfolitixorin/5-FU-based chemotherapy”

Poster at ASCO-GI 2021 >>

Helena Taflin, et al. ” Plasma deoxyuridine as a surrogate marker for toxicity and early clinical response in patients with metastatic colorectal cancer after 5-FU-based therapy in combination with arfolitixorin”

Springer Link, October, 2020 >>

Heinz-Josef Lenz, et al. “An open-label Phase III study of arfolitixorin vs leucovorin in modified FOLFOX-6 for first-line treatment of metastatic colorectal cancer”

Poster at ASCO-GI 2020 >>

Stintzing, Sebastian, et al. “Open-label Phase III Study of Arfolitixorin vs Leucovorin in Modifi ed FOLFOX-6 for First-line Treatment of Metastatic Colorectal Cancer: AGENT”.
Poster at ESMO 2019 >>

Carlsson, Göran, et al. “ISO-CC-005; a phase I/II study of arfolitixorin ([6R]-5,10-MTHF) in combination with 5-fluorouracil (5-FU), irinotecan and oxaliplatin ± bevacizumab in patients with metastasizing colorectal cancer”.
Poster at ESMO 2018 >>

Gustavsson, Bengt, et al. “Folate gene prediction of treatment response to 5-FU and leucovorin in metastasizing colorectal cancer”.
Poster at ASCO 2018  >>

Gustavsson, Bengt, et al. “A review of the evolution of systemic chemotherapy in the management of colorectal cancer”.
Clinical colorectal cancer 14.1 (2015): 1-10 >>

Danenberg, Peter V., et al. “Folates as adjuvants to anticancer agents: Chemical rationale and mechanism of action”.
Critial Reviews in Oncology/Hematology 106 (2016): 118-131 >>

Taflin, Helena, et al. “Folate levels measured by LC–MS/MS in patients with colorectal cancer treated with different leucovorin dosages.”
Cancer chemotherapy and pharmacology 74.6 (2014): 1167-1174 >>